Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidence
- 23 November 2006
- Vol. 333 (7578), 1114-1117
- https://doi.org/10.1136/bmj.39000.486701.68
Abstract
Cohort studies Meta-analyses of cohort studies show significant positive associations between serum homocysteine concentrations and ischaemic heart disease events (fatal and non-fatal myocardial infarction and sudden cardiac death) and stroke. A 3 µmol/l decrease in serum homocysteine (achievable with 0.8 mg/day folic acid) lowers the risk of myocardial infarction by 15% and stroke by 24%.1 3 These estimates were adjusted for confounding by other cardiovascular risk factors.Keywords
This publication has 21 references indexed in Scilit:
- Homocysteine Lowering and Cardiovascular Events after Acute Myocardial InfarctionNew England Journal of Medicine, 2006
- Folate Therapy and In-Stent Restenosis after Coronary StentingNew England Journal of Medicine, 2004
- The dose-response relation between serum homocysteine and cardiovascular disease: implications for treatment and screeningEuropean Journal of Preventive Cardiology, 2004
- Lowering Homocysteine in Patients With Ischemic Stroke to Prevent Recurrent Stroke, Myocardial Infarction, and DeathJAMA, 2004
- Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysisBMJ, 2003
- Homocysteine and cardiovascular disease: evidence on causality from a meta-analysisBMJ, 2002
- MTHFR 677C→T Polymorphism and Risk of Coronary Heart DiseaseJAMA, 2002
- Homocysteine and Risk of Ischemic Heart Disease and StrokeJAMA, 2002
- Decreased Rate of Coronary Restenosis after Lowering of Plasma Homocysteine LevelsNew England Journal of Medicine, 2001
- THE NATURAL-HISTORY OF HOMOCYSTINURIA DUE TO CYSTATHIONINE BETA-SYNTHASE DEFICIENCY1985